Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23408230 | 1.00 | USP30 (0.39) | USP30BTKP2RX7GAADRD2 | |
| SCHEMBL20772980 | 1.00 | USP30 (0.39) | USP30BTKP2RX7GAADRD2 | |
| SCHEMBL20849978 | 0.93 | P2RX7 (0.42) | USP30BTKP2RX7GAADRD2 | |
| SCHEMBL24767056 | 0.90 | DRD2 (0.35) | USP30BTKGAADRD2KDM1A | |
| SCHEMBL25117807 | 0.90 | AAK1 (0.37) | USP30BTKGAADRD2KDM1A | |
| SCHEMBL25608671 | 0.89 | GAA (0.39) | USP30BTKGAAKDM1AMAOB | |
| SCHEMBL25608660 | 0.89 | GAA (0.39) | USP30BTKGAAKDM1AMAOB | |
| SCHEMBL16386070 | 0.89 | GAA (0.39) | USP30BTKGAAKDM1AMAOB | |
| SCHEMBL23067074 | 0.88 | MAPK1 (0.37) | USP30BTKP2RX7GAADRD2 | |
| SCHEMBL20850170 | 0.87 | P2RX7 (0.47) | USP30BTKP2RX7GAADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843656-A | Thiophene [3,2-d ] pyrimidine derivative, and preparation method and application thereof | 四川大学华西医院 | 2024-04-09 | — | — | CN | claimed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709730-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12544359-B2 | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | Infex Therapeutics Limited (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544359-B2 | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | CBR1, CBR3, SRR | USP30 4168/4885BTK 756/4885P2RX7 1886/4885 |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | USP30 3298/4885BTK 400/4885P2RX7 941/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | USP30 3/4885BTK 3557/4885P2RX7 4395/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | USP30 3281/4885BTK 2347/4885P2RX7 735/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | USP30 2690/4885BTK 1047/4885P2RX7 4332/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | USP30 1711/4885BTK 120/4885P2RX7 1935/4885 |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | GRM2, GRIN2C, GRM1 | USP30 2995/4885BTK 4005/4885P2RX7 287/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | USP30 4663/4885BTK 3480/4885P2RX7 1597/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | USP30 2690/4885BTK 1047/4885P2RX7 4332/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | USP30 3062/4885BTK 914/4885P2RX7 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.